All In Biotech

Drug Trial Radar · NCT02045056

Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease

Last checked: Nov 20, 2026Latest source record: Oct 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

May 2014

Primary completion

Jun 30, 2018

Study completion Jun 2019

Sponsor

Lead sponsor
Gregory Jicha, 323-5550Academic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 24, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 65 years, up to 90 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and efficacy of gemfibrozil in modulating microRNA-107 levels for the prevention of Alzheimer's disease in subjects with intact cognition and mild cognitive impairment

Conditions

  • Preclinical Alzheimer's Disease

Interventions

  • GemfibrozilDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SafetyTime frame: 52 weeks
  2. microRNA-107 levelsTime frame: 48 weeks
  3. beta-amyloid levelsTime frame: 48 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Kentucky

    Lexington, Kentucky

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.